Filing Details

Accession Number:
0001209191-22-053597
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-10-13 18:09:47
Reporting Period:
2022-10-11
Accepted Time:
2022-10-13 18:09:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1812364 Relay Therapeutics Inc. RLAY Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1816210 Sanjiv Patel C/O Relay Therapeutics, Inc.
399 Binney Street, 2Nd Floor
Cambridge MA 02139
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-10-11 14,000 $4.12 268,554 No 4 M Direct
Common Stock Disposition 2022-10-11 14,000 $21.36 254,554 No 4 S Direct
Common Stock Acquisiton 2022-10-12 14,000 $4.12 268,554 No 4 M Direct
Common Stock Disposition 2022-10-12 14,000 $21.18 254,554 No 4 S Direct
Common Stock Acquisiton 2022-10-13 14,000 $4.12 268,554 No 4 M Direct
Common Stock Disposition 2022-10-13 14,000 $20.58 254,554 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-10-11 14,000 $0.00 14,000 $4.12
Common Stock Stock Option (Right to Buy) Disposition 2022-10-12 14,000 $0.00 14,000 $4.12
Common Stock Stock Option (Right to Buy) Disposition 2022-10-13 14,000 $0.00 14,000 $4.12
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
60,175 2028-03-22 No 4 M Direct
46,175 2028-03-22 No 4 M Direct
32,175 2028-03-22 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 674,548 Indirect By The Patel Family Irrevocable Trust of 2019
Common Stock 432,801 Indirect By The SSP Irrevocable Trust of 2020
Footnotes
  1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022.
  2. This transaction was executed in multiple trades at prices ranging from $20.76 to $21.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. This transaction was executed in multiple trades at prices ranging from $20.78 to $21.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. This transaction was executed in multiple trades at prices ranging from $20.28 to $20.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  5. These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  6. The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date.